Navigation Links
Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Date:5/30/2009

Data Presented at 45th American Society of Clinical Oncology Annual Meeting

Abstracts: 5033, 3560

ORLANDO, Fla., May 30 /PRNewswire/ -- Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Bayer is committed to discovering new cancer-fighting therapies," said Kemal Malik, MD, Chief Medical Officer and Head of Global Development at Bayer HealthCare. "We are encouraged by these Phase I and II data being presented on BAY 73-4506. These data will help further determine our next steps as we move forward with a comprehensive Phase III clinical development program in various tumor types for this new drug candidate."

Preliminary data from the Phase II, open-label study in renal cell carcinoma (RCC) demonstrated a 27 percent partial response (PR) rate according to the Response Evaluation Criteria in Solid Tumors (RECIST) and a disease control rate of 79 percent. The most common drug-related adverse events were hand-foot skin reaction (HFSR), fatigue, hypertension, mucositis, dysphonia, rash, diarrhea, and anorexia. The Phase II study enrolled 49 previously untreated patients with predominantly clear cell RCC. BAY 73-4506 (160 mg) was administered once daily on a three weeks on/one week off schedule. The primary endpoint was to evaluate response rate according to RECIST.

"We are encouraged by these data of BAY 73-4506," said lead investigator Professor Tim Eisen, F.R.C.P., PhD, of Addenbrooke's Hospital at the University of Cambridge, UK. "These data provide a rationale to move into a Phase III trial in one of the multiple tumor types that may be responsive to BAY 73-4506."

Additional data presented on BAY 73-4506 include a Phase I study of patients with advanced refractory colorectal carcinoma (CRC). The data were presented by lead investigator Dirk Strumberg, MD, Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Germany.

Data from the Phase I dose-finding study in CRC showed BAY 73-4506, dosed at 160 mg daily, using a treatment schedule of 21 days on/7 days off, was feasible in patients with advanced refractory CRC. Disease control rate (PR + SD) was 74 percent in evaluable patients. The most common drug-related adverse events were hand-foot skin reaction (HFSR), fatigue, hoarseness, mucositis, diarrhea, anorexia and hypertension. Data presented are based on 38 patients with actively progressing CRC enrolled in a Phase I study. Patients were treated with BAY 73-4506 at doses of 60 mg, 120 mg, 160 mg, and 220 mg once daily.

About BAY 73-4506 (DAST-Inhibitor)

BAY 73-4506 is a dual targeted VEGFR2-TIE2 anti-angiogenic oral tyrosine kinase inhibitor (TKI) with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). In preclinical studies, BAY 73-4506 has been shown to inhibit tumor growth by hitting targets along a spectrum of angiogenic pathways, including VEGFR and TIE2. BAY 73-4506 has also been shown in preclinical studies to prevent the proliferation of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The clinical significance of these studies is not known and warrant further investigation in a broad spectrum of tumors.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a subsidiary of Bayer Corporation. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. The company's aim is to provide products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Details on the studies can be found on the ASCO website: www.abstract.asco.org.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
Breaking Medicine News(10 mins):